Buy Generic Desogestrel And Ethinyl Estradiol Online

Generic Desogestrel And Ethinyl Estradiol Information

Introduction

Desogestrel and Ethinyl Estradiol is a combined oral contraceptive (COC) that belongs to the therapeutic groups Women’s Health and Birth Control. The product contains the synthetic progestogen desogestrel and the synthetic estrogen ethynyl estradiol. In the United Kingdom it is prescribed for prevention of unintended pregnancy and for certain menstrual‑related conditions. The formulation is marketed by several multinational manufacturers, and it is also available as a generic product that matches the active ingredients of the original brand names such as Marvelon, Desogen and Desograv.

What is Desogestrel And Ethinyl Estradiol?

Desogestrel and Ethinyl Estradiol is a fixed‑dose combination tablet that delivers a low‑dose estrogen (ethinyl estradiol ≈ 30 µg) together with a third‑generation progestogen (desogestrel ≈ 150 µg). It is classified as a hormonal contraceptive, a pharmacologic agent that suppresses ovarian function and modifies the endometrium. The product is produced by manufacturers approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and is listed on the NHS BNF under the section “Combined hormonal contraceptives, oral”.

How Desogestrel And Ethinyl Estradiol Works

The estrogen component stabilises the endometrium, reducing menstrual‑related breakthrough bleeding, while the progestogen component inhibits the luteinising hormone (LH) surge that triggers ovulation. Desogestrel binds to the progesterone receptor with high affinity, exerting a negative feedback on the hypothalamic‑pituitary‑ovarian axis. Ethinyl estradiol, a potent estrogen, suppresses follicle‑stimulating hormone (FSH) release, thereby preventing follicular maturation. The combined effect results in:

• No ovulation in > 97 % of cycles when tablets are taken correctly.
• Thickened cervical mucus, hindering sperm penetration.
• Altered endometrial development, impairing implantation.

Pharmacokinetic studies in healthy women show peak plasma concentrations of desogestrel‑metabolite (etonogestrel) within 3–4 hours after ingestion, a half‑life of ≈ 27 hours, and steady‑state after ~ 1 week of daily dosing. Ethinyl estradiol reaches maximum levels in 1–2 hours, is metabolised by hepatic CYP3A4, and has a half‑life of ≈ 20 hours. Both compounds are cleared primarily via the liver and excreted in urine and bile.

Conditions Treated with Desogestrel And Ethinyl Estradiol

Suitable Candidates for Desogestrel And Ethinyl Estradiol Treatment

• Women aged 15 – 49 years with an intact uterus who desire reliable contraception and have no contraindications to estrogen‑containing products.
• Patients with a history of menstrual irregularities who seek cycle regularity without surgical intervention.
• Individuals with moderate to severe acne where conventional dermatologic therapy is insufficient.
• Women who have previously tolerated COCs and prefer a low‑dose estrogen/progestogen regimen.

Not appropriate in the presence of any of the following risk factors:

• Personal history of venous thromboembolism, myocardial infarction, or stroke.
• Active or past hormone‑sensitive malignancy (e.g., breast or endometrial cancer).
• Major hepatic disease or cirrhosis.
• Uncontrolled hypertension (> 160/100 mmHg).
• Known hypersensitivity to desogestrel, ethynyl estradiol, or any tablet excipients.

Clinical assessment should include a review of the UK NICE guideline on combined hormonal contraceptives and the MHRA prescribing criteria before initiation.

Risks, Side Effects, and Interactions

Common

• Nausea or mild vomiting (≈ 5 % of users).
• Breast tenderness or enlargement.
• Headache, including migraine (≈ 3 %).
• Weight fluctuations (generally modest).
• Spotting or breakthrough bleeding during the first 2–3 months of use.

Rare

• Mood changes, depressive symptoms, or decreased libido.
• Visual disturbances (e.g., transient blurred vision).
• Skin reactions at the site of medication (e.g., rare contact dermatitis from tablet coating).

Serious

• Venous thromboembolosis (VTE) – risk is increased 3‑ to 4‑fold compared with non‑users; absolute risk ≈ 1–2 per 10 000 woman‑years.
• Myocardial infarction or stroke, particularly in smoking women > 35 years.
• Severe hepatic dysfunction or cholestatic jaundice.
• Hypertensive crisis (rare, severe elevation of BP).

Drug–drug interactions

• Enzyme inducers (e.g., rifampicin, carbamazepine, St John’s wort) increase clearance of ethynyl estradiol, potentially reducing contraceptive efficacy.
• Enzyme inhibitors (e.g., ketoconazole, HIV protease inhibitors) raise estradiol concentrations, heightening thrombotic risk.
• Antiepileptic drugs such as carbamazepine and phenytoin may lower desogestrel metabolite levels, requiring backup contraception.
• Antibiotics (e.g., griseofulvin) have not shown clinically relevant reductions in efficacy; no dosage adjustment is needed.
• Antifungal agents (e.g., fluconazole) and antiretrovirals (e.g., efavirenz) may have modest interactions; a barrier method is advisable during concomitant use.

Patients should disclose all current medications, including over‑the‑counter products and herbal supplements, to the prescribing clinician.

Practical Use: Dosing, Missed Dose, Overdose

Standard dosing – one tablet taken at the same time each day for 21 consecutive days followed by a 7‑day pill‑free interval (or placebo tablets) during which withdrawal bleeding occurs. Tablet strength is typically 30 µg ethinyl estradiol + 150 µg desogestrel.

Missed dose –

• If a dose is missed by < 24 hours, take the tablet immediately and continue the regular schedule (no double‑dose).
• If > 24 hours have elapsed, take the missed tablet as soon as possible, then use a reliable backup method (e.g., condom) for the next 48 hours.

Overdose –

• Ingesting > 5 times the intended dose may cause nausea, vomiting, and breast tenderness.
• Immediate medical attention is advised; symptomatic treatment (e.g., activated charcoal) is supportive.
• No specific antidote exists; management focuses on observation and supportive care.

Precautions –

• Food does not significantly affect absorption; tablets may be taken with or without meals.
• Alcohol in moderation does not affect efficacy, but heavy drinking (> 6 units per day) increases VTE risk and should be avoided.
• Patients with hepatic impairment need dose modification; regular liver function monitoring is recommended.
• Smoking > 15 cigarettes per day contraindicates estrogen‑containing COCs in women > 35 years.

Buying Desogestrel And Ethinyl Estradiol from Our Online Pharmacy

Desogestrel And Ethinyl Estradiol can be purchased from our online pharmacy in the UK. We source the product from MHRA‑registered overseas suppliers that meet stringent quality‑assurance standards, ensuring that the generic tablets contain the exact same active ingredients as the original branded preparations.

• Affordable pricing – our wholesale rates are close to the manufacturer’s list price, offering a cost‑effective alternative for patients seeking long‑term contraception.
• Verified quality – each batch is accompanied by a Certificate of Analyse and is stored under controlled conditions to protect potency.
• Guaranteed delivery – discreet packaging is dispatched within 7 working days using express courier services, with a standard airmail option of 3 weeks for non‑express shipments.
• Privacy‑first service – as a pharmacy‑broker, we work with licensed overseas pharmacies and suppliers, enabling a discreet service that respects patient confidentiality while complying with UK import regulations.

Our online pharmacy therefore provides a reliable, safe, and economical route for patients whose access to regular pharmacy dispensing is limited.

FAQ

• **Is Desogestrel And Ethinyl Estradiol available in both brand‑name and generic forms in the UK?**
  Yes. The combination is marketed under several brand names (e.g., Marvelon, Desogen) and also as a generic tablet containing desogestrel + ethinyl estradiol. The generic version is chemically identical and is usually priced lower than the branded products.

• **What are the visual characteristics of the tablets?**
  Tablets are typically round, 5 mm in diameter, and film‑coated. One side bears a colour (commonly light‑pink) and imprint indicating the hormone content, while the opposite side may be blank or display the manufacturer’s logo.

• **Does the medication require refrigeration?**
  No. Desogestrel And Ethinyl Estradiol tablets are stable at room temperature (15 – 30 °C) and should be stored away from moisture and direct sunlight. Extreme heat above 40 °C can degrade the active ingredients over time.

• **Can the pills be taken while travelling abroad?**
  Yes. As long as the tablets are taken at the same time each day, short‑term travel does not affect efficacy. Carry a written record of the dosing time when crossing time‑zone boundaries to avoid accidental double‑dosing.

• **How is the product packaged for international dispatch?**
  Each order is sealed in a tamper‑evident envelope with internal cushioning. The outer packaging includes the product name, dosage strength, batch number, and an optional patient‑information leaflet in English.

• **Is personal import of Desogestrel And Ethinyl Estradiol into the UK permitted?**
  The UK permits personal import of prescription‑only medicines for personal use if the total quantity does not exceed a three‑month supply and the importer holds a valid prescription. Our service ensures that all shipments comply with HMRC and MHRA import regulations.

• **Are there specific warnings for women of Asian descent?**
  Population‑based studies have identified a slightly higher incidence of VTE among East‑Asian women using combined oral contraceptives when smoking. Clinicians should assess individual risk factors and advise against smoking in all ethnic groups.

• **Do formulation differences exist between EU and US products?**
  EU‑authorized combined tablets typically contain 30 µg ethynyl estradiol, whereas some US formulations may provide 20 µg. Desogestrel doses are consistent (150 µg) across regions. These variations influence haemostatic risk profiles and should be considered when switching between markets.

• **What major clinical trials supported the approval of this combination?**
  Large Phase III trials, such as the MECO Study (1998) and subsequent meta‑analyses of > 6 million cycles, demonstrated a ≥ 99 % effectiveness in preventing pregnancy with a safety profile comparable to other low‑dose COCs. The data underpin the NHSD and MHRA endorsement of desogestrel + ethinyl estradiol.

• **How does the presence of ethinyl estradiol affect drug testing for employment?**
  Standard workplace drug screens do not detect hormonal contraceptives. However, high levels of estrogen metabolites may be identified in specialized endocrine panels, which are rarely ordered for employment screening unless a medical review is requested.

• **Are there any known differences in inactive ingredients across manufacturers?**
  While the active ingredients are identical, excipients such as lactose, magnesium stearate, and polymeric coating may vary. Patients with known allergies to these components should review the specific product leaflet before use.

Glossary

Combined oral contraceptive (COC)

A medication that contains both an estrogen and a progestogen to inhibit ovulation and provide contraception.

Progestogen

A synthetic compound that mimics the action of natural progesterone, binding to progesterone receptors and exerting anti‑gonadotropic effects.

Venous thromboembolism (VTE)

A condition encompassing deep‑vein thrombosis and pulmonary embolism, associated with increased clotting risk in estrogen‑exposed women.

CYP3A4

A liver enzyme responsible for metabolising many drugs, including ethynyl estradiol; variations in its activity can alter drug exposure.

⚠️ Disclaimer

The information provided about Desogestrel And Ethinyl Estradiol is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Desogestrel And Ethinyl Estradiol for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.